Risk of Production and Sales Stoppages Due to COVID-19 Infections and a Second Wave
First written in FY2020-Q3. 9 of 15 entries say "Restated". Latest entry: FY2024.
Micron Machinery moved to the "Worse" side of this theme in 2020, 3 years before the typical company in this theme (2023).
The whole theme swung hardest in 2025: 2 of 12 companies on the "Worse" side.
7 other companies' latest entry also says "Dropped".
- FY2024DroppedAnnual report
「During the current consolidated fiscal year, the Japanese economy continued to show signs of a gradual recovery as socioeconomic activity normalized following the reclassification of COVID-19 as a Class 5 disease, although some stagnation was observed.」
The risk of production and sales suspensions due to a second wave or employee infections, which had been disclosed as a separate business risk, is not listed separately among the current period's risks. The economic overview describes the normalization of socioeconomic activity following the reclassification of COVID-19 as a Class 5 disease. - FY2024-Q2RestatedAnnual report
「During the six-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of production and sales suspensions due to COVID-19 infection and a second wave. - FY2023DroppedAnnual report
「With COVID-19 reclassified as a Class 5 disease, activity restrictions were lifted and socioeconomic activity began returning to normal」
The current list of business risks no longer contains a separate item for the risk of production and sales suspensions due to a second wave or employee infections. The economic overview describes the reclassification of COVID-19 as a Class 5 disease and the lifting of activity restrictions. - FY2023-Q3RestatedAnnual report
「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of production and sales suspensions due to COVID-19 infection and a second wave. - FY2023-Q2RestatedAnnual report
「During the six-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of production and sales suspensions due to COVID-19 infection and a second wave. - FY2023-Q1RestatedAnnual report
「During the three-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of production and sales suspensions due to COVID-19 infection and a second wave. - FY2022-Q3RestatedAnnual report
「COVID-19 has continued to cause repeated outbreaks as the virus mutates. Because it is difficult to predict when the pandemic will subside, the company expects its impact to continue for the time being.」
The company continues to describe repeated outbreaks caused by viral mutations and the expectation that the pandemic's impact will continue for the time being. - FY2022-Q2RestatedAnnual report
「COVID-19 has continued to cause repeated outbreaks as the virus mutates. Because it is difficult to predict when the pandemic will subside, the company expects its impact to continue for the time being.」
The disclosure describes repeated outbreaks caused by viral mutations and the expectation that the pandemic's impact will continue for the time being. - FY2022-Q1RestatedAnnual report
「It is difficult to predict when the COVID-19 pandemic will subside. Overseas, infections are spreading again due to highly infectious variants, and the situation remains unpredictable. Accordingly, the company expects the impact of the pandemic to continue for the time being.」
The disclosure describes the renewed spread of infection overseas due to highly infectious variants and the expectation that the impact will continue for the time being. - FY2021WorsenedAnnual report
「The situation remains unpredictable, with outbreaks of highly infectious variants and reported cases of infection even after 2 vaccine doses. The possibility cannot be ruled out that the movement of people may again be restricted due to simultaneous outbreaks with seasonal influenza and other infectious diseases, or that employees and others working for the group may become infected with COVID-19. In such an event, production and sales activities could be suspended or restricted for a certain period, potentially having a significant impact on the group's business results and other conditions.」
In addition to the risks of a second wave and employee infections, the company identifies highly infectious variants, infections after vaccination and simultaneous outbreaks with other infectious diseases as new uncertainties. - FY2021-Q3RestatedAnnual report
「During the nine-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company continues to identify the risk of production and sales suspensions due to COVID-19 infection and a second wave, stating that there have been no material changes. - FY2021-Q2RestatedAnnual report
「During the six-month cumulative period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company continues to identify the risk of production and sales suspensions due to COVID-19 infection and a second wave, stating that there have been no material changes. - FY2021-Q1MaterialisedAnnual report
「The Group (the Company and its consolidated subsidiaries) has also been affected mainly overseas by partial restrictions on sales activities involving visits to customers and by the inability to conduct some commissioning tests after delivery, which are performed to install machinery and ensure machining accuracy.」
Although production and sales activities have not been completely suspended due to the spread of infection, restrictions on sales visits, mainly overseas, and the inability to conduct some delivery commissioning activities have actually occurred. - FY2020WorsenedAnnual report
「The global spread of infection remains unchecked, and in Japan the situation continues to be unpredictable, with infections spreading from major metropolitan areas to regional areas and clusters being reported in workplaces and homes. The possibility cannot be ruled out that the movement of people may again be restricted due to simultaneous outbreaks with seasonal influenza and other infectious diseases, or that employees and others working for the group may become infected with COVID-19. In such an event, production and sales activities could be suspended or restricted for a certain period.」
The scope of the risk of production and sales suspensions due to a second wave or employee infections has expanded to include the global spread of infection, domestic clusters and simultaneous outbreaks with other infectious diseases. - FY2020-Q3First statedAnnual report
「It is difficult to predict when the COVID-19 pandemic will subside. Although conditions have been moving toward containment, with the lifting of the state of emergency and the easing of requests to refrain from travel across prefectural borders, the possibility of a second wave or employees and others working for the group becoming infected with COVID-19 cannot be ruled out. In such an event, production and sales activities could be suspended or restricted for a certain period, potentially having a significant impact on the group's business results and other conditions.」
Separate from the previously described impact on the economy and order intake, the company has for the first time expressly identified the suspension or restriction of production and sales activities triggered by a second wave or employee infections as an additional business risk.